Increasing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment of small cell lung cancer, among many other malignancies, and are now routinely added to first-line therapy (Horn et al., 2018; Zhou et al., 2020). This evidence concerns the gene CD274 and small cell lung carcinoma.